D-Pharm Climbs Most in Two Weeks on Deal to Acquire Thrombotech

D-Pharm Ltd. (DPRM) rose the most in more than two weeks after the biopharmaceutical company reached an initial agreement to buy Thrombotech Ltd., which is developing a peptide that improves the efficiency of stroke medication.

The shares of the Nes Ziona, Israel-based company rose 8 percent, the biggest intraday advance since April 19, to 1.011 shekels at 3:11 p.m. in Tel Aviv.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.